Leagans v. LeMaitre Vascular Inc

CourtDistrict Court, D. South Carolina
DecidedOctober 12, 2021
Docket2:21-cv-01866
StatusUnknown

This text of Leagans v. LeMaitre Vascular Inc (Leagans v. LeMaitre Vascular Inc) is published on Counsel Stack Legal Research, covering District Court, D. South Carolina primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Leagans v. LeMaitre Vascular Inc, (D.S.C. 2021).

Opinion

IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF SOUTH CAROLINA CHARLESTON DIVISION

LAWRENCE LEAGANS, ) ) Plaintiff, ) ) No. 2:21-cv-01866-DCN vs. ) ) ORDER LEMAITRE VASCULAR, INC., ) ) Defendant. ) _______________________________________)

The following matter is before the court on defendant LeMaitre Vascular Inc’s (“LeMaitre”) motion to dismiss, transfer, or stay, ECF No. 6, and plaintiff Lawrence Leagans’s (“Leagans”) motion to advance declaratory judgment determination and for a speedy hearing, ECF No. 8. For the reasons set forth below, the court grants LeMaitre’s motion to dismiss. As a result, the court finds Leagans’s motion to advance declaratory judgment moot. I. BACKGROUND LeMaitre is a medical device company that develops, manufactures, and sells devices for the treatment of peripheral vascular disease. Leagans is a former employee of LeMaitre. He began working at LeMaitre on or around March 23, 2009 as a sales representative covering South Carolina and Georgia. When Leagans resigned from the company in April 2021, he served as the regional sales manager for the “East Region,” which covered eleven states extending from South Carolina to New Jersey. Throughout the duration of his employment with LeMaitre, Leagans lived and worked in Charleston County, South Carolina. As a condition of his employment, Leagans executed an Employee Obligations Agreement (“Agreement”). The Agreement contained several restrictive covenants, including a covenant not to compete, a nonsolicitation provision, and a nondisclosure provision. The relevant provisions are below. 2. Covenant Not to Compete. Employee agrees that the services to be rendered by him or her to the Company are special and unique. During the period commencing on the date of this Agreement and ending two (2) years after the termination of Employees’ engagement or employment by the company in any capacity, Employee shall not, as an owner, part-owner, partner, director, officer, trustee, employee, agent, consultant, joint venturer, stockholder, representative, sole proprietor, independent contractor or in any other capacity directly or indirectly engage in or participate in any activity, business, organization or entity (i) which is either carried on, located or doing business in any state of the United States and (ii) which is in competition with the then existing or planned business of the Company, including without limitation, any products or services then being developed, produced, manufactured, provided or marketed by the Company. ECF No. 1-1 ¶ 2. 3. Nonsolicitation. During the period commencing on the date of this Agreement and ending two (2) years from the termination of Employee’s employment with the Company, the Employee shall not, as an owner, part- owner, partner, director, officer, trustee, employee, agent, consultant, joint venturer, stockholder, sole representative, sole proprietor or independent contractor, or in any other capacity or on behalf of any other person or entity, directly or indirectly (a) solicit, divert or take away any existing customer or business of the Company, or (b) hire, engage, retain, or solicit as an employee, consultant or in any other capacity any person employed by the Company at the time of, or at any time in the twelve-month period prior to, such hiring, engagement, retention or solicitation. Id. ¶ 3. 5. Nondisclosure Obligation. (a) The Employee will not, at any time, whether during or after the termination of employment, for any reason whatsoever, use for his or her own benefit or the benefit of any person or entity other than the Company or disclose to any person or entity (both commercial and noncommercial) any of the following information either regarding the Company of regarding any of its customers, clients, contractors, consultants, licensees or affiliates if held in confidence by the Company, except for such disclosures as may be required by the Company in the ordinary course of the Employee performing his or her duties as an employee of the Company: trade secrets or confidential business information, including research and development activities; computer software; product designs, prototypes and technical specifications; show- how and knowhow; business plans and strategies; pricing and costing policies; customer and supplier lists; and nonpublic financial information (the “Confidential Information”). Id. ¶ 5(a). The agreement also contains a provision stating that “[t]his Agreement shall be governed by, and construed in accordance with, the internal laws of the Commonwealth of Massachusetts, without regard to conflicts of laws principles thereof.” Id. ¶ 11. Leagans resigned from LeMaitre on April 30, 2021 to accept a position with Silk Road Medical Inc. (“Silk Road”). By all accounts, LeMaitre and Silk Road are generally competitors, as both companies manufacture and sell medical devices for the treatment of vascular disease. At Silk Road, Leagans serves as a principal area manager covering the territory of South Carolina. Leagans alleges that after he was hired, he would be in training and onboarding until September or October 2021, and after that, he would begin selling a medical device that does not compete with the LeMaitre device that Leagans previously sold. ECF No. 1, Compl. ¶¶ 20, 46. According to Leagans, the devices are used to treat different vascular issues. Id. ¶ 22. According to LeMaitre, however, Leagans had previously suggested that there would be “100% overlap” of surgeons who use both devices. ECF No. 6-1 at 2 (citing ECF No. 1-2). After learning that Leagans had accepted a position with Silk Road, LeMaitre’s general counsel raised concerns about a potential violation of LeMaitre’s noncompetition agreement. On May 21, 2021, counsel for LeMaitre followed up with a cease-and-desist letter to Leagans, writing that “[y]our employment by Silk Road as Principal Area Manager constitutes breach of your non-compete restriction.” ECF No. 1-2. In response, Leagans’s counsel spoke with LeMaitre’s counsel over the phone on May 25, 2021. During that call, Leagans alleges that his counsel indicated that Leagans would be in training for four to six weeks, that Leagans would not pose a threat to LeMaitre’s business interests, and that the parties should seek a mutually agreeable resolution during

that time. Compl. ¶ 44–45. On June 17, 2021, LeMaitre filed a complaint in the District of Massachusetts (the “Massachusetts court”), alleging breach of restrictive covenants and seeking injunctive relief (the “Massachusetts Action”). LeMaitre Vascular Inc. v. Leagans, No. 1:21-cv- 11012-NMG (D. Mass. 2021) (ECF No. 1) (hereinafter, “Mass. Dkt.” et seq.). LeMaitre provided a courtesy copy of the complaint to Leagans’s counsel within hours of filing. ECF No. 9 at 6. The next day, June 18, 2021, Leagans filed a complaint in this court, requesting a declaratory judgment finding the restrictive covenants in the Agreement to be invalid. See Compl.

In the Massachusetts Action, Leagans filed a motion to dismiss or, in the alternative, to stay or transfer the case to this court on August 13, 2021. Mass. Dkt. 12. Leagans’s motion was referred to a magistrate judge. The magistrate judge issued an R&R on September 30, 2021 recommending against dismissal or transfer.1 Mass. Dkt. 30.

1 Although LeMaitre appealed to that R&R in a letter to the court, ECF No. 18, the court does not consider the magistrate judge’s findings in the Massachusetts Action probative to this action. The primary decision of whether the Massachusetts Action should be dismissed or transferred is within the province of the Massachusetts court. Likewise, this court must independently determine whether dismissal or transfer is appropriate in this action. As such, the R&R in the Massachusett’s Action does not In the instant matter, LeMaitre likewise filed a motion to dismiss, transfer, or stay on July 9, 2021. ECF No. 6.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Klaxon Co. v. Stentor Electric Manufacturing Co.
313 U.S. 487 (Supreme Court, 1941)
BHP International Investment, Inc. v. Online Exchange, Inc.
105 F. Supp. 2d 493 (E.D. Virginia, 2000)
Nucor Corp. v. Bell
482 F. Supp. 2d 714 (D. South Carolina, 2007)
Byerson v. Equifax Information Services, LLC
467 F. Supp. 2d 627 (E.D. Virginia, 2006)
Speed Trac Technologies, Inc. v. Estes Express Lines, Inc.
567 F. Supp. 2d 799 (M.D. North Carolina, 2008)
Shipley Co., Inc. v. Clark
728 F. Supp. 818 (D. Massachusetts, 1990)
TGG Ultimate Holdings, Inc. v. Hollett
224 F. Supp. 3d 275 (S.D. New York, 2016)

Cite This Page — Counsel Stack

Bluebook (online)
Leagans v. LeMaitre Vascular Inc, Counsel Stack Legal Research, https://law.counselstack.com/opinion/leagans-v-lemaitre-vascular-inc-scd-2021.